Corcept Therapeutics Inc (NASDAQ: CORT)

Sector: Healthcare Industry: Biotechnology CIK: 0001088856
P/B 14.57
P/E 87.99
P/S 12.42
Market Cap 9.21 Bn
ROIC (Qtr) 13.27
Div Yield % 0.00
Rev 1y % (Qtr) 13.75
Total Debt (Qtr) 6.36 Mn
Debt/Equity (Qtr) 0.01

About

Stock Price Chart

Analysis

Pros

  • Strong operating cash flow of 162.85M provides robust 25.61x coverage of total debt 6.36M, indicating excellent debt servicing capability and financial flexibility.
  • Healthy cash reserves of 125.14M provide 119.18x coverage of short-term debt 1.05M, demonstrating strong liquidity position and minimal refinancing risk.
  • Operating cash flow of 162.85M provides exceptional 111.31x coverage of minority interest expenses 1.46M, showing strong core operations.
  • Strong tangible asset base of 823.61M provides 129.54x coverage of total debt 6.36M, indicating robust asset backing and low credit risk.
  • Robust free cash flow of 162.57M exceeds capital expenditure of 282000 by 576.48x, indicating strong organic growth funding capability.

Cons

  • Investment activities of 17.24M provide weak support for R&D spending of 260.35M, which is 0.07x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • High receivables of 69.63M relative to inventory of 24.35M (2.86 ratio) suggests aggressive credit terms or collection difficulties, potentially masking revenue quality issues.
  • The company's operating cash flow of 162.85M shows concerning coverage of stock compensation expenses of 80.53M, with a 2.02 ratio indicating potential earnings quality issues.
  • Operating cash flow of 162.85M provides minimal -9.25x coverage of tax expenses of (17.60M), suggesting potential tax planning inefficiencies or unsustainable tax positions.
  • Long-term investments of 102.56M represent a high 14.93x of fixed assets 6.87M, indicating potential overexposure to financial assets versus operational capabilities.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 11.06 12.31
EV to Cash from Ops. 55.95 23.25
EV to Debt 1,433.12 738.44
EV to EBIT 142.13 -9.16
EV to EBITDA 135.11 6.95
EV to Free Cash Flow [EV/FCF] 56.05 21.90
EV to Market Cap 0.99 65.67
EV to Revenue 12.29 227.32
Price to Book Value [P/B] 14.57 22.34
Price to Earnings [P/E] 87.99 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage -2.79 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 86.25 -27.13
Cash and Equivalents Growth (1y) % -8.85 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -36.25 -46.93
EBITDA Growth (1y) % -53.33 -1.68
EBIT Growth (1y) % -54.86 -56.45
EBT Growth (1y) % -47.24 -12.70
EPS Growth (1y) % -26.47 -28.31
FCF Growth (1y) % 14.42 -31.90
Gross Profit Growth (1y) % 17.62 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.90 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 0.73 3.85
Current Ratio 3.14 7.27
Debt to Equity Ratio 0.01 0.40
Interest Cover Ratio -2.79 841.00
Times Interest Earned -2.79 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 8.90 -18,234.31
EBIT Margin % 8.65 -18,580.80
EBT Margin % 11.74 -19,488.74
Gross Margin % 98.20 -7.59
Net Profit Margin % 14.10 -19,439.22